On September 11, 2025, Professor Guo Yanwu, Director of the Neurorestoration Professional Committee of Guangdong Medical Doctor Association and Director of Functional Neurosurgery at the Neurosurgery Center of Zhujiang Hospital, Southern Medical University, led a research team to visit Shenzhen-Hong Kong Cell Valley for an investigative and exchange activity. The team was warmly received by Professor Shi Yuan Yuan, Chairman of Cell Valley Group, and Dr. Xiang Hua, Co-founder. Both parties engaged in in-depth and productive discussions on the clinical research and translational applications of cell therapy and exosome technology platforms in neurological diseases.

Powerful Collaboration to Tackle Clinical Challenges Together

Neurological diseases such as Alzheimer's, Parkinson's, post-stroke recovery, and traumatic brain injury have long plagued hundreds of millions of patients worldwide. Currently, effective clinical treatments are limited, and there is an urgent need for innovative therapies to address the vast unmet medical demands.

Leveraging its advanced cell production platform and large-scale exosome preparation capabilities, Cell Valley Group has laid a solid foundation for clinical research and translational applications related to neurological diseases. Some of its products have demonstrated remarkable neurorestorative potential in preclinical studies, featuring low immunogenicity and excellent targeting, offering new hope for overcoming the limitations of traditional treatments.

As a renowned expert in neurosurgery, Professor Guo Yanwu has over 20 years of clinical experience, specializing in the precise diagnosis and minimally invasive treatment of refractory epilepsy. He has also accumulated extensive expertise in microsurgery for brain and spinal cord tumors, hydrocephalus treatment, coma awakening, microvascular decompression for trigeminal neuralgia and hemifacial spasm, and neuromodulation therapy. Professor Guo is committed to advancing the clinical translation of cutting-edge research to benefit more patients.

Moving Forward Together to Accelerate Clinical Translation

Both parties agreed that the collaboration would capitalize on Cell Valley's strengths in technological innovation and industrial translation, as well as Zhujiang Hospital's capabilities in clinical research and discipline development, to jointly advance the safety and efficacy validation of cell and exosome-based therapies for neurological diseases.

Looking ahead, both teams will build upon the consensus reached in this exchange to accelerate the clinical application and trial processes, striving to achieve results translation at the earliest opportunity and bring new hope to patients with neurological disorders worldwide.